Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07136012 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

StatusRecruiting
PhasePhase 3
SponsorAmgen
Started2025-08-22
View on ClinicalTrials.gov ↗
The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Amendment record

Amended 35 times since 2025-08-18; most recent filed 2026-08-20. Every amendment is listed below.

Dates here are the day the sponsor filed the amendment, not the day ClinicalTrials.gov published it. Version history last read from ClinicalTrials.gov on 2026-08-30.

2026-08-20
Amendment Study Status, Contacts/Locations v35
2026-08-12
Amendment Study Status, Contacts/Locations v34
2026-08-05
Amendment Study Status, Contacts/Locations v33
2026-07-09
Amendment Study Status, Contacts/Locations v32
2026-06-24
Amendment Study Status, Contacts/Locations v31
2026-06-17
Amendment Study Status, Contacts/Locations v30
2026-06-03
Amendment Study Status, Contacts/Locations v29
2026-05-27
Amendment Study Status, Contacts/Locations v28
2026-05-20
Amendment Study Status, Contacts/Locations v27
2026-05-14
Amendment Study Status, Contacts/Locations v26
2026-05-07
Amendment Study Status, Contacts/Locations v25
2026-04-29
Amendment Study Status, Contacts/Locations v24
2026-04-22
Amendment Study Status, Contacts/Locations v23
2026-04-15
Amendment Study Status, Contacts/Locations v22
2026-04-10
Amendment Study Status, Contacts/Locations v21
2026-04-01
Amendment Study Status, Contacts/Locations v20
2026-03-24
Amendment Study Status, Contacts/Locations v19
2026-03-04
Amendment Study Status, Contacts/Locations v18
2026-02-25
Amendment Study Status, Contacts/Locations v17
2026-02-18
Amendment Study Status, Contacts/Locations v16
2026-02-11
Amendment Study Status, Contacts/Locations v15
2026-02-04
Amendment Study Status, Contacts/Locations v14
2026-01-28
Amendment Study Status, Contacts/Locations v13
2026-01-21
Amendment Study Status, Contacts/Locations v12
2026-01-14
Amendment Study Status, Contacts/Locations v11
2026-01-07
Amendment Study Status, Contacts/Locations v10
2025-12-31
Amendment Study Status, Contacts/Locations v9
2025-12-10
Amendment Study Status, Contacts/Locations v8
2025-12-03
Amendment Study Status, Contacts/Locations v7
2025-11-12
Amendment Study Status, Contacts/Locations v6
2025-10-29
Amendment Study Status, Contacts/Locations v5
2025-10-22
Amendment Study Status, Contacts/Locations v4
2025-10-01
Amendment Study Status, Contacts/Locations v3
2025-09-24
Amendment Study Status, Contacts/Locations v2
2025-09-16
Amendment Study Status, Contacts/Locations v1
2025-08-18
Original filing
Trial Details
NCT Number NCT07136012
Lead Sponsor Amgen
Conditions Cardiovascular Disease
Enrollment 11,000 participants
Start Date 2025-08-22
Primary Completion 2031-10-20 (estimated)
Study Completion 2031-10-20 (estimated)
Updated on ClinicalTrials.gov 2026-08-21